Sheaff Brock Investment Advisors LLC Raises Stock Position in Medpace Holdings, Inc. (NASDAQ:MEDP)

Sheaff Brock Investment Advisors LLC boosted its stake in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) by 0.7% in the fourth quarter, HoldingsChannel.com reports. The fund owned 5,515 shares of the company’s stock after purchasing an additional 39 shares during the period. Sheaff Brock Investment Advisors LLC’s holdings in Medpace were worth $1,832,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in the stock. R Squared Ltd acquired a new position in shares of Medpace during the 4th quarter worth about $30,000. Stone House Investment Management LLC purchased a new stake in Medpace during the 3rd quarter worth approximately $33,000. Ashton Thomas Securities LLC acquired a new position in shares of Medpace during the third quarter valued at approximately $37,000. Capital Performance Advisors LLP purchased a new position in shares of Medpace in the third quarter valued at approximately $46,000. Finally, True Wealth Design LLC boosted its stake in shares of Medpace by 16,800.0% in the third quarter. True Wealth Design LLC now owns 169 shares of the company’s stock worth $56,000 after acquiring an additional 168 shares during the last quarter. 77.98% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of research analysts have weighed in on the company. Robert W. Baird raised their price objective on Medpace from $354.00 to $362.00 and gave the company a “neutral” rating in a report on Monday, January 27th. William Blair reissued an “outperform” rating on shares of Medpace in a research note on Tuesday, October 22nd. TD Cowen lowered their price target on shares of Medpace from $413.00 to $372.00 and set a “buy” rating on the stock in a research report on Wednesday, October 23rd. Finally, Baird R W downgraded shares of Medpace from a “strong-buy” rating to a “hold” rating in a report on Wednesday, October 23rd. Seven research analysts have rated the stock with a hold rating and five have issued a buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $381.44.

Medpace Price Performance

Medpace stock opened at $340.17 on Friday. The firm has a 50 day simple moving average of $343.50 and a 200-day simple moving average of $348.31. The stock has a market cap of $10.57 billion, a price-to-earnings ratio of 29.79, a price-to-earnings-growth ratio of 1.85 and a beta of 1.36. Medpace Holdings, Inc. has a 1-year low of $302.01 and a 1-year high of $459.77.

Medpace (NASDAQ:MEDP) last issued its quarterly earnings data on Monday, February 10th. The company reported $3.67 earnings per share for the quarter, topping the consensus estimate of $2.96 by $0.71. Medpace had a return on equity of 50.87% and a net margin of 17.66%. Equities analysts expect that Medpace Holdings, Inc. will post 11.93 earnings per share for the current fiscal year.

About Medpace

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.